News | December 03, 2007

Drug-Eluting Stents Improve Patient Outcomes in Routine Practice

December 4, 2007 - In general, drug-eluting stents (DES) achieve better results than bare-metal stents do, U.S. researchers report in the November 20 issue of the Journal of the American College of Cardiology.

"We found that DES, as they are being used in clinical practice in North America, significantly reduce the need for target vessel revascularization compared to bare-metal stents," lead investigator J. Dawn Abbott, M.D., told Reuters Health.

"Importantly," she added, this reduction "was observed in patients with and without complex coronary lesion types."

Dr. Abbott of Rhode Island Hospital, Providence, and colleagues studied data from 2004 for 1460 patients who received at least one DES. These data were compared with earlier records for 1,763 patients who received at least one bare-metal stent.

At one year, the cumulative death and myocardial infarction rate was 7.6 percent in DES patients and 8.7 percent in bare-metal stent patients, a nonsignificant difference. The corresponding rate of target vessel revascularization at one year was 5.0 percent and 9.2 percent (p

In DES patients, the one-year hazard ratio for any repeat vascularization by percutaneous coronary intervention or coronary bypass was 0.38, and the rate of stent thrombosis was 1 percent.

"These improved outcomes," continued Dr. Abbott, "were achieved without any evidence of increased hazard from DES use, as demonstrated by similar one-year rates of death and myocardial infarction, and a very low rate of angiographically confirmed late stent thrombosis."

"While these results certainly confirm the efficacy of DES," she concluded, "we will need longer follow-up to evaluate the incidence of very late stent thrombosis in these patients."

In an accompanying editorial, Franz-Josef Neumann, M.D., Herz-Zentrum, Bad Krozingen, Germany writes that the "mounting evidence on this matter confirms the superior efficacy of DES with respect to the prevention of repeat revascularization and does not suggest inferior safety compared with bare-metal stents."

Ref: J Am Coll Cardiol 2007;50:2029-2038
Source: Reuters Health, December 3, 2007

For more information: www.acc.org

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init